FILTER

Refine your search with the following facets to narrow down your results.

7 Current news of Shionogi

MorphoSys and Shionogi Agree Three-Year Extension of Research Partnership

04-Nov-2011 - MorphoSys AG announced that it has expanded its current licence agreement withShionogi & Co., Ltd., Osaka, Japan. The expanded agreement covers the use of MorphoSys'sHuCALantibody technology and additional proprietary technology modules for research in drug discovery for three additional years ...

MorphoSys

Evotec Achieves Two Milestones in Fragment-based Drug Discovery Alliance with Shionogi

03-Nov-2011 - Evotec AG announced the achievement of specific success criteria in a multiple target drug discovery collaboration with Shionogi & Co Ltd. and the receipt of two milestone payments. Evotec and Shionogi will continue to collaborate to progress the fragments through the drug discovery process. The ...

drug discovery Evotec milestone payments

Graffinity Enters into Drug Discovery Collaboration with Shionogi

31-Mar-2011 - Graffinity Pharmaceuticals GmbH announced that it has entered into a research collaboration with Osaka, Japan based Shionogi & Co., Ltd. Under the terms of the agreement, Graffinity will receive technology access fees and payments for follow-up chemistry for the generation of various, novel small ...

research collaborations

Evotec and Shionogi Enter Fragment-based Drug Discovery Alliance

07-Oct-2010 - Evotec AG announced that it has entered into a multiple target drug discovery collaboration with Shionogi & Co Ltd., to identify small molecule modulators of various protein-protein interaction targets. Evotec will apply its proprietary and integrated fragment-based drug discovery platform, ...

drug discovery collaborations evolution Evotec +4

Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan

08-Sep-2010 - Stallergenes S.A. has announced the signing of exclusive partnership agreements with Shionogi & Co., Ltd. for two sublingual allergen immunotherapy tablet products resulting from the Stalair(R) program: Actair(R) house dust mite tablets and Japanese cedar pollen tablets. With 32 million ...

allergic rhinitis allergies antihistamines

Shionogi Extends Research Partnership with MorphoSys

30-Sep-2008 - MorphoSys AG announced that Shionogi & Co., Ltd. has elected to extend its current license agreement covering the use of MorphoSys's HuCAL technology in drug discovery, for three additional years. Under the terms of the agreement, Shionogi will continue to have the right to use MorphoSys's ...

gold license agreements MorphoSys

Shionogi & Co., Ltd. to Acquire Sciele Pharma, Inc.

03-Sep-2008 - Shionogi & Co., Ltd. and Sciele Pharma, Inc. announced that they have entered into a definitive agreement under which Shionogi & Co., Ltd. will acquire Sciele Pharma, Inc. Under the terms of agreement and pursuant to a tender offer, Shionogi will acquire all the outstanding shares of Sciele’s ...

business development reductions